NetApp, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

$7 Billion Gone: DRAM ETF Investors Crushed As Memory Chip Mania Unravels

DRAM ETF investors face $7 billion in estimated losses as a 40% plunge rattles the artificial intelligence memory chip trade.

'TSMC Weighs Making Advanced Memory Chips to Capture More AI Spending' - The Information

Ultragenyx Announces UK MHRA Acceptance of Marketing Authorisation Application for Rebisufligene Etisparvovec

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted the Marketing Authorisation Application for Ultragenyx's investigational gene therapy, rebisufligene etisparvovec, for the treatment of MPS IIIA.

SK Hynix Shares Decline Amid Broader Semiconductor Market Sell-Off

SK Hynix shares experienced a significant decline as part of a broader technology sector sell-off triggered by concerns over artificial intelligence infrastructure spending.

Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

Ultragenyx announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) accepted its Marketing Authorisation Application for rebisufligene etisparvovec (UX111), an investigational gene therapy for MPS IIIA (Sanfilippo syndrome Type A). The company has also coordinated with NICE to align the evaluation timeline with the regulatory review process. The therapy received FDA approval in September 2026 and is also under review by the European Medicines Agency.

Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $32